For the price of a good men's suit, a batch of new services will scan your genes and spot potential health risks, from cancer to lower back pain.

According to an Associated Press story on Page M11, the services are the business world's answer to a deluge of new genetic discoveries pouring forth from scientists' labs. Key investors in two of the companies, 23andMe Inc. and Navigenics Inc., are among the biggest names in new technology.

But some analysts and investors wonder if consumers are ready to trust these startups when their own fine print warns against using their information to make serious medical decisions.

"I am a bit skeptical that many people are going to pay $1,000 for information that's not very useful just for entertainment value," said Douglas M. Fambrough, a biotech venture capitalist with Oxford Bioscience Partners in Boston.

"I would say that getting your whole genome sequenced is really at this point just a vanity exercise."